Form 4: Entera Bio R&D Chief Receives Stock Grant

Gregory Burshtein, Chief of R&D at Entera Bio, received 87,591 restricted stock units in lieu of a cash bonus.

Summary

• Gregory Burshtein, Chief of R&D at Entera Bio Ltd., was granted 87,591 restricted stock units (RSUs).
• The grant was approved by the Board of Directors on May 7, 2026.
• The RSUs were issued in lieu of a cash bonus previously owed to the executive.
• The units vest ratably on a quarterly basis over a one-year period starting May 1, 2026.
• Following this transaction, the reporting person holds a total of 189,033 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event reflecting standard executive compensation practices rather than a change in company fundamentals.

Positives

• The grant aligns executive compensation with long-term shareholder interests through equity ownership.
• The company preserves cash by settling a bonus obligation with stock.

Negatives

• The issuance of new shares results in minor dilution to existing shareholders.

Risks

• Future share price volatility may impact the ultimate value realized by the executive from these RSUs.

Future Outlook

The RSUs will vest in equal quarterly installments over the one-year period ending in 2027.

Management Comments

• The grant was awarded in lieu of a cash bonus the reporting person was otherwise entitled to.

Industry Context

StockSavvy.ai notes that it is common practice for small-cap biotech firms to utilize equity-based compensation to preserve cash reserves for clinical development and operational expenses.

Comparison to Industry Standards

• The use of stock-settled RSUs in lieu of cash is a standard mechanism for cash-constrained biotech companies to manage liquidity.
• The one-year vesting schedule is relatively aggressive compared to the typical three-to-four-year vesting schedules seen in larger pharmaceutical companies.

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Quarterly vesting of the granted RSUs over the next 12 months.

Key Dates

Keywords

Entera Bio, ENTX, Form 4, Insider Trading, Executive Compensation, Restricted Stock Units